Generic Medicine Info
Indications and Dosage
Allergic conditions
Adult: As immediate-release tab/soln: 4-8 mg 3-4 times daily. As extended-release susp: 6-16 mg 12 hrly. Dosage should be individualised based on response and severity of condition.
Elderly: Initiate at lower end of dosing range.
Child: As immediate-release preparation: 2-5 yr As soln: 1-2 mg 3-4 times daily; 6-11 yr As tab/soln: 2-4 mg 3-4 times daily; ≥12 yr Same as adult dose. As extended-release susp: 2-3 yr 3-4 mg 12 hrly; 4-5 yr 3-8 mg 12 hrly; 6-11 yr 6-12 mg 12 hrly; ≥12 yr Same as adult dose.
Should be taken with food.
Concomitant use w/ MAOIs. Childn <2 yr. Lactation.
Special Precautions
Patient w/ asthma, increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, CV disease, HTN, stenosing peptic ulcer, prostatic hypertrophy, bladder neck and pyloroduodenal obstructions. Elderly. Pregnancy.
Adverse Reactions
Urticaria, rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dry mouth, nose, and throat; epigastric distress, anorexia, nausea, vomiting, diarrhoea, constipation; hypotension, headache, palpitations, tachycardia, extrasystoles; fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paraesthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsion, sedation, drowsiness, dizziness, disturbed coordination; increased uric acid levels; chest tightness, wheezing, nasal stuffiness, thickening of bronchial secretions; urinary frequency, difficult urination, urinary retention, early menses; haemolytic anaemia, thrombocytopenia, agranulocytosis.
Patient Counseling Information
This drug may cause drowsiness and impaired mental or physical ability, if affected, do not drive or operate machinery.
Symptoms: Fixed and dilated pupils, dry mouth, flushing, GI symptoms, hallucinations, convulsions. Management: Symptomatic and supportive treatment. Employ activated charcoal and gastric lavage after ingestion of potentially life-threatening amount. Treat severe antimuscarinic effects w/ physostigmine. Treat hypotension w/ vasopressors.
Drug Interactions
May increase the effect of other antihistamines, barbiturates, TCAs, and CNS depressants (e.g. hypnotics, sedatives, tranquilisers).
Potentially Fatal: MAOIs (e.g. phenelzine, tranylcypromine, selegiline) may prolong and intensify the anticholinergic effects of carbinoxamine.
Food Interaction
May increase the effect of alcohol.
Mechanism of Action: Carbinoxamine, an ethanolamine derivative, is a sedating antihistamine w/ antimuscarinic and significant sedative properties. It competes w/ histamine in binding to H1-receptors on effector cells in the resp tract, blood vessels, and GI tract.
Duration: Approx 4 hr (immediate-release).
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 1.5-5 hr.
Metabolism: Extensively metabolised in the liver.
Excretion: Via urine (as inactive metabolites). Elimination half-life: 10-20 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Carbinoxamine, CID=2564, (accessed on Jan. 21, 2020)

Store between 15-30°C. Protect from light.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AA08 - carbinoxamine ; Belongs to the class of aminoalkyl ethers used as systemic antihistamines.
Anon. Carbinoxamine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/11/2016.

Buckingham R (ed). Carbinoxamine Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/11/2016.

Carbinoxamine Maleate Tablet and Syrup (Breckenridge Pharamaceutical, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/11/2016.

Karbinal ER Suspension, Extended Release (FSC Laboratories, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/11/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Carbinoxamine Maleate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 15/11/2016.

Disclaimer: This information is independently developed by MIMS based on Carbinoxamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in